Navigation Links
Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity
Date:6/9/2009

Study Indicated Rasagiline Selectivity for Inhibiting MAO-B at Maximum Approved Dose

KANSAS CITY, Mo., June 9 /PRNewswire/ -- Teva Neuroscience, Inc. today presented results from a clinical pharmacology study in which AZILECT(R) (rasagiline tablets) did not increase the risk of tyramine sensitivity at the maximum approved dose of 1 mg. The presentation was made during the 13th International Congress of Parkinson's Disease and Movement Disorders in Paris, France. This study assessed the potential risk of hypertensive crisis due to the interaction between high doses of oral tyramine and therapeutic doses of rasagiline, which is indicated both as monotherapy in patients with early Parkinson's disease (PD) and as adjunctive treatment in patients receiving levodopa. The study supported the selectivity of rasagiline for inhibition of MAO-B at currently approved doses.

"We are pleased with the results, which met our primary objectives," said Jon Congleton, general manager of Teva Neuroscience. "This study provides continuing evidence of the value of AZILECT. The results demonstrated a low potential for MAO-A and therefore a selectivity for MAO-B inhibition."

The clinical pharmacology trial was a double-blind, placebo-controlled, randomized, dose-ranging study of rasagiline using a positive control (phenelzine) and a comparator drug (selegiline). The study results were based on the Tyramine Sensitivity Factor (TSF), which measures the ratio of tyramine pressor dose before (baseline) and after MAO inhibitor administration. Geometric mean TSFs of all doses of rasagiline were substantially lower than the TSF for phenelzine, a known nonselective MAO inhibitor. TSFs of various doses of rasagiline were comparable to those of selegiline and placebo.

Tyramine is an amino acid found in certain foods and beverages, including some air-dried and fermented meats, some aged cheeses and most soybean products. Non
'/>"/>

SOURCE Teva Neuroscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
2. LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit
3. PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice
4. Document Management Inefficiencies Cost Clinical Study Sites Time, Money
5. ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
6. Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use
7. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
8. FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
9. Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
10. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... DC (PRWEB) July 28, 2014 It’s a ... GI Bill benefits to further their post-secondary education are failing ... a study released this year. And according to an analysis ... this shortfall is veteran students’ uninformed choice of college majors, ... The details of the study: Some 51.7 percent of post-9/11 ...
(Date:7/28/2014)... 28, 2014 Research and Markets has ... Market 2014-2018" report to their offering. ... is a technique used to determine the size of a ... is crucial to analyze the size of particles as it ... analysis is performed to determine the behavior and nature of ...
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... Directors today declared a $0.61 per share dividend for ... paid on Sept. 5, 2014, to all stockholders of ... 14, 2014.  About Amgen Amgen is ... suffering from serious illnesses by discovering, developing, manufacturing and ...
(Date:7/25/2014)... According to a new market report ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... estimated at USD 161,056.5 million in 2014 and is ... 2014 to 2020, to reach an estimated value of ... market is witnessing a significant growth due to the ...
Breaking Biology Technology:Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4Global Particle Size Analysis Market 2014-2018 2Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3
... /PRNewswire-Asia-FirstCall/  - China Cord Blood Corporation (NYSE: ... largest cord blood banking operator in China, today announced ... which allowed warrant holders to receive one ordinary share ... ordinary shares, equivalent to 2.2% of shares outstanding as ...
... BioTrends Research Group, Inc. finds that with ... (DMA) for the treatment of multiple sclerosis (MS), neurologists anticipate ... month after the launch of Gilenya, trial and uptake of ... to be tempered due to the perception that Extavia is ...
... December 9, 2010 Scientists from Pacific Biosciences of ... successfully employed single molecule, real-time (SMRT) DNA sequencing technology ... deadly cholera epidemic in Haiti. Published Thursday in ... results provide the first whole genome sequence analysis and ...
Cached Biology Technology:China Cord Blood Corporation Announces Completion of Warrant Exchange 2With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 2With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 3Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen 2Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen 3
(Date:7/27/2014)... and fungi can evade treatment by acquiring mutations in ... permanent mutations were once thought to be the only ... study has shown that microorganisms can use a temporary ... to gain the benefits of drug resistance without the ... a fungus called Mucor circinelloides, it is likely to ...
(Date:7/27/2014)... at Barts Cancer Institute have found that targeting a ... more effective, according to research published in Nature ... part of Queen Mary University of London, have found ... the body to repair itself after chemotherapy or radiotherapy, ... researchers removed FAK from blood vessels that grew in ...
(Date:7/27/2014)... 18,000 patients, scientists have identified more than two ... including six that had not been previously reported. ... was partially funded by the National Institutes of ... NIH laboratories. , "Unraveling the genetic underpinnings of ... involved in this complex disease, and hopefully, may ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New drug target can break down cancer's barrier against treatment 2NIH scientists find 6 new genetic risk factors for Parkinson's 2
... laser laboratory operational later this year, he will use ... bonds like a stringed musical instrument. Tokmakoff, the ... at the University of Chicago in January to tackle ... vibrational spectroscopy methods that he has developed. "He ...
... Cognitive impairments are disabling for individuals with schizophrenia, ... affect a wide range of cognition, including memory, ... appear in the earliest stages of the disease ... Scientists are exploring a variety of strategies ...
... 2013 Shiner Beers, the popular Texas craft brew, will ... for Diabetes Research at the Translational Genomics Research Institute (TGen). ... kick off on Wednesday, March 13, at the Hotel San ... Conferences & Festivals. The noon-8 p.m. event, themed after ...
Cached Biology News:Watery research theme to flow through new Tokmakoff lab 2Watery research theme to flow through new Tokmakoff lab 3Tickling the brain with magnetic stimulation improves memory in schizophrenia 2Shiner Beers launches nationwide support of TGen diabetes studies 2
... Dithiothreitol DTT White solid.. ... disulfides to thiols, so reaction is "driven" to ... not contain waxy surfactant found in many other ... pentobarbitol. Purity: ≥97% by titration. ...
... This kit is designed for easy transformation ... protocol allows for successful transformation simply by ... reagents with cultured yeast cells. No complicated ... are required. The kit is particularly well ...
... for easy transformation of the budding yeast, ... transformation simply by mixing a plasmid DNA ... cells. No complicated steps, such as centrifugation ... is particularly well suited for high-throughput transformation ...
... pro balance increases your lab productivity and allows ... and regulatory compliance. Move ahead beyond traditional paper-based ... data system. *Instruments supported: ... MX, UMX, AG, XS, XP, PR, SR, PG-S, ...
Biology Products: